Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BCMA-GPRC5D CAR-T in Relapsed/Refractory Multiple Myeloma
NCT06515262Recruiting
- Start
- Jul 2024
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of BCMA/GPRC5D CAR-T in multiple myeloma (MM). Primary endpoint: Incidence of adverse events (AE) after infusion. Started Jul 2024; status: recruiting.
02
Drugs
BCMA/GPRC5D CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06515262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06515262.